Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Clal Biotechnology Industries Current Ratio?
Clal Biotechnology IndustriesXTAE:CBI 18 Current Ratio is 0.14 as of Dec. 2025, which is 95% below its 10-year median of 3.08. GuruFocus rates XTAE:CBI with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Clal Biotechnology Industries ranks worse than 96.17% on this metric.
Clal Biotechnology Industries has a current ratio of 0.14. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Clal Biotechnology Industries has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Clal Biotechnology Industries's Current Ratio or its related term are showing as below:
XTAE:CBI'
s Current Ratio Range Over the Past 10 Years
Min: 0.14 Med: 3.08 Max: 7.46
Current: 0.14
During the past 13 years, Clal Biotechnology Industries's highest Current Ratio was 7.46. The lowest was 0.14. And the median was 3.08.
XTAE:CBI's Current Ratio is ranked worse than 96.17% of 1409
companies
in the Biotechnology industry
Industry Median: 3.85
vs XTAE:CBI: 0.14
Clal Biotechnology Industries (XTAE:CBI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Clal Biotechnology Industries Current Ratio Related Terms
Clal Biotechnology Industries Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:CBI vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Clal Biotechnology Industries's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clal Biotechnology Industries Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Current Ratio distribution charts can be found below:
* The bar in red indicates where Clal Biotechnology Industries's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clal Biotechnology Industries (XTAE:CBI) has a Current Ratio of 0.14 as of Dec. 2025. This is 95% below median its historical median of 3.08. Over the past decade, Clal Biotechnology Industries' Current Ratio has ranged from 0.14 to 7.46. According to the industry distribution chart, Clal Biotechnology Industries ranks #1355 out of 1409 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Clal Biotechnology Industries' Current Ratio too high?
Clal Biotechnology Industries' current Current Ratio of 0.14 is 95% below median its 10-year median of 3.08. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 7.46. The Biotechnology industry median Current Ratio is 3.85. Clal Biotechnology Industries' value of 0.14 is 96.4% below this industry median. Based on the distribution chart, Clal Biotechnology Industries ranks #1355 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clal Biotechnology Industries has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Clal Biotechnology Industries' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clal Biotechnology Industries ranks #1355 out of 1409 companies for Current Ratio. This places Clal Biotechnology Industries in the lower half of its industry. The industry median Current Ratio is 3.85. Clal Biotechnology Industries' value of 0.14 is 96.4% below this benchmark. Historically, Clal Biotechnology Industries' own Current Ratio has ranged from 0.14 to 7.46 over the past decade. While the company's 10-year median is 3.08 vs. the industry median of 3.85, Clal Biotechnology Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clal Biotechnology Industries's current Current Ratio of 0.14 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clal Biotechnology Industries's current Current Ratio is 0.14, which is 95% below median its own 10-year median of 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Biotechnology Industries stock overvalued right now?
Clal Biotechnology Industries (XTAE:CBI) has a current Current Ratio of 0.14. The current Current Ratio is 0.14, which is 95% below median its 10-year median of 3.08 and 96.4% below the Biotechnology industry median of 3.85. Clal Biotechnology Industries' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Clal Biotechnology Industries (XTAE:CBI), the current Current Ratio is 0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
18GF Score
Get the complete analysis for XTAE:CBI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:CBI has been successfully added to your 
